Clinical Trials Directory

Trials / Unknown

UnknownNCT00002887

Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer

PHASE I TRIAL OF HYDROXYUREA FOR SALVAGE OF INCURABLE NON-SMALL CELL LUNG CANCER

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Ottawa Regional Cancer Centre · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells. PURPOSE: Phase I trial to study the effects of hydroxyurea plus combination chemotherapy in patients with non-small cell lung cancer.

Detailed description

OBJECTIVES: I. Estimate the maximum tolerated dose of hydroxyurea that can be given in combination with other chemotherapy regimens in patients with incurable non-small cell lung cancer. II. Determine the toxicity of this combination chemotherapy regimen in these patients. III. Observe the efficacy of hydroxyurea in patients with incurable non-small cell lung cancer refractory to front-line chemotherapy. OUTLINE: This study seeks to estimate the maximum tolerated dose (MTD) of hydroxyurea in combination with other chemotherapy. Groups of 3 patients take escalated doses of oral hydroxyurea three times weekly or daily throughout treatment with cisplatin plus (per their previous regimen) vinblastine, vindesine, vinorelbine, or etoposide. Treatment continues in responding and stable patients until 3 months beyond documentation of complete remission (minimum 4 courses), maximum of 6 courses beyond documentation of partial remission, or 3 courses beyond documentation of stable disease. Patients are followed every 3 weeks for 3 months, every 6 weeks for 3 months, then every 3 months until disease progression. PROJECTED ACCRUAL: An anticipated 15-30 patients will be entered.

Conditions

Interventions

TypeNameDescription
DRUGcisplatin
DRUGetoposide
DRUGhydroxyurea
DRUGvinblastine sulfate
DRUGvindesine
DRUGvinorelbine tartrate
PROCEDUREdrug resistance inhibition treatment

Timeline

Start date
1995-07-01
First posted
2004-03-26
Last updated
2013-09-17

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00002887. Inclusion in this directory is not an endorsement.